HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
AuthorsAndrew D Zelenetz, Leo I Gordon, William G Wierda, Jeremy S Abramson, Ranjana H Advani, C Babis Andreadis, Nancy Bartlett, John C Byrd, Myron S Czuczman, Luis E Fayad, Richard I Fisher, Martha J Glenn, Thomas M Habermann, Nancy Lee Harris, Richard T Hoppe, Steven M Horwitz, Christopher R Kelsey, Youn H Kim, Susan Krivacic, Ann S LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A Saad, Lubomir Sokol, Lode J Swinnen, Christina Tsien, Julie M Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, National comprehension cancer network
JournalJournal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 13 Issue 3 Pg. 326-62 (Mar 2015) ISSN: 1540-1413 [Electronic] United States
PMID25736010 (Publication Type: Journal Article, Practice Guideline)
CopyrightCopyright © 2015 by the National Comprehensive Cancer Network.
Topics
  • Algorithms
  • Comorbidity
  • Disease Management
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis, epidemiology, etiology, therapy)
  • Neoplasm Staging
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: